In the clinical space, applications such as phenotypical and morphological changes in red blood cell structure in sickle cell disease17–19, hereditary spherocytosis20, red blood cell storage lesions21,22, phenotypic blast heterogeneity23, assessment of leukocyte-platelet aggregates24, detection of numerical and structural chromosomal abnormalities25–27, and detection of cytoplasmic nucleophosmin in NPM1 mutated AML patients28,29 show the potential strength of IFC. Here, NPM1 is linked to acute myeloid leukemia.